Hormonal contraception using a vaginal ring which releases estriol and trimegestone
WO2020112818A1
Drug device combination for the effective treatment of incontinence in women
US2020087340A1
Lif/lifr antagonist in oncology and nonmalignant diseases
WO2020056349A2
Lif/lifr antagonist oncology and nonmalignant diseases
AU2019261454A1
Estrogen prodrugs and methods of administering estrogen prodrugs
EP3697421A1
Longer-acting progestin prodrug contraceptives
US2017319833A1
Intravaginal drug delivery device
MX2017012068A
Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents.
WO2016090139A1
Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
AU2014287049A1
Pro-drug forming compounds
MX2015016550A
Imidazolyl progesterone antagonists.
WO2013071210A1
Methods for the preparation of etonogestrel and desogestrel
AU2012286648A1
Progesterone antagonists
AU2011238710B2
Intravaginal drug delivery device
EP2417149A1
Methods for the preparation of drospirenone
WO2010118025A1
Progesterone antagonists spiro condensed in position 17 with a difluoromethylene- substituted perhydrofurane group
